MiniSOX9, a dominant-negative variant in colon cancer cells

Oncogene

Volumn 30, Issue 22, 2011, Pages 2493-2503

  Abdel Samad, R ^a   Zalzali, H ^a   Rammah, C ^a   Giraud, J ^a   Naudin, C ^a   Dupasquier, S ^a   Poulat, F ^b   Boizet Bonhoure, B ^b   Lumbroso, S ^c   Mouzat, K ^c   Bonnans, C ^a   Pignodel, C ^c   Raynaud, P ^a   Fort, P ^b   Quittau Prevostel C ^a   Blache, P ^a  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b CNRS   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

PKC ; SOX9; Wnt b catenin signaling pathway

Indexed keywords

BETA CATENIN; MESSENGER RNA; PROTEIN KINASE C ALPHA; TRANSCRIPTION FACTOR SOX9; WNT PROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; GENE ACTIVITY; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE POLYP; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLICING DEFECT;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENES, DOMINANT; HUMANS; INTRONS; MICE; MICE, MUTANT STRAINS; MOLECULAR SEQUENCE DATA; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-ALPHA; SOX9 TRANSCRIPTION FACTOR; WNT PROTEINS;

EID: 79957903265     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.621     Document Type: Article

References (40)

1. Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E et al. (2002). RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 21: 7850-7860. (Pubitemid 35398843)
2. Agrawal R, Wessely O, Anand A, Singh L, Aggarwal RK. (2009). Male-specific expression of Sox9 during gonad develop-ment of crocodile and mouse is mediated by alternative splicing of its proline-glutamine-alanine rich domain. FEBS J 276: 4184-4196.
3. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. (2002). The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 2813-2828. (Pubitemid 35253149)
4. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ et al. (2008). Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 98: 466-473. (Pubitemid 351161244)
5. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ et al. (2009). Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 136: 2325-2333.
6. Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C et al. (2007). Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium. J Cell Biol 178: 635-648. (Pubitemid 47267275)
7. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN et al. (2004). SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 166: 37-47. (Pubitemid 38931915)
8. Brinkman BM. (2004). Splice variants as cancer biomarkers. Clin Biochem 37: 584-594. (Pubitemid 38845021)
9. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H et al. (1998). Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395: 604-608. (Pubitemid 28475714)
10. Chaboissier MC, Kobayashi A, Vidal VI, Lutzkendorf S, van de Kant HJ, Wegner M et al. (2004). Functional analysis of Sox8 and Sox9 during sex determination in the mouse. Development 131: 1891-1901. (Pubitemid 38702025)
11. Chen M, Manley JL. (2009). Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10: 741-754.
12. Cheung M, Chaboissier MC, Mynett A, Hirst E, Schedl A, Briscoe J. (2005). The transcriptional control of trunk neural crest induction, survival, and delamination. Dev Cell 8: 179-192. (Pubitemid 40197735)
13. Colnot S, Niwa-Kawakita M, Hamard G, Godard C, Le Plenier S, Houbron C et al. (2004). Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 84: 1619-1630. (Pubitemid 39600569)
14. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantama-diotis T et al. (2008). Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res 68: 4258-4268.
15. Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D et al. (2009). A new mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium. J Cell Sci 122: 2191-2196.
16. Foster JW, Dominguez-Steglich MA, Guioli S, Kowk G, Weller PA, Stevanovic M et al. (1994). Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 372: 525-530. (Pubitemid 24368528)
17. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA et al. (1989). Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63: 280-288. (Pubitemid 19035019)
18. Gilmartin GM. (2005). Eukaryotic mRNA 3' processing: a common means to different ends. Genes Dev 19: 2517-2521. (Pubitemid 41565970)
19. Giordano J, Prior HM, Bamforth JS, Walter MA. (2001). Genetic study of SOX9 in a case of campomelic dysplasia. Am J Med Genet 98: 176-181. (Pubitemid 32051806)
20. Houston CS, Opitz JM, Spranger JW, Macpherson RI, Reed MH, Gilbert EF et al. (1983). The campomelic syndrome: review, report of 17 cases, and follow-up on the currently 17-year-old boy first reported by Maroteaux et al. in 1971. Am J Med Genet 15: 3-28. (Pubitemid 13120140)
21. Hu J, Lutz CS, Wilusz J, Tian B. (2005). Bioinformatic identification of candidate cis-regulatory elements involved in human mRNA polyadenylation. RNA 11: 1485-1493. (Pubitemid 41396918)
22. Jay P, Berta P, Blache P. (2005). Expression of the carcinoembryonic antigen gene is inhibited by SOX9 in human colon carcinoma cells. Cancer Res 65: 2193-2198. (Pubitemid 40490127)
23. Jin L, Li Y, Chen CJ, Sherman MA, Le K, Shively JE. (2008). Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain. Exp Biol Med (Maywood) 233: 849-859.
24. Kamachi Y, Uchikawa M, Kondoh H. (2000). Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 16: 182-187. (Pubitemid 30169154)
25. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW et al. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC?/\colon carcinoma. Science 275: 1784-1787. (Pubitemid 27136714)
26. Lee JY, Ji Z, Tian B. (2008). Phylogenetic analysis of mRNA polyadenylation sites reveals a role of transposable elements in evolution of the 3'-end of genes. Nucleic Acids Res 36: 5581-5590.
27. Leung N, Turbide C, Balachandra B, Marcus V, Beauchemin N. (2008). Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1?/\mice. Oncogene 27: 4943-4953.
28. MacDonald BT, Tamai K, He X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC Science 275: 1787-1790. (Pubitemid 27136715)
30. Muller P, Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA et al. (2010). SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat 120: 317-326.
31. Notarnicola C, Malki S, Berta P, Poulat F, Boizet-Bonhoure B. (2006). Transient expression of SOX9 protein during follicular development in the adult mouse ovary. Gene Expr Patterns 6: 695-702. (Pubitemid 44103528)
32. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y et al. (2009). Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 119: 954-963.
33. Pysz MA, Leontieva OV, Bateman NW, Uronis JM, Curry KJ, Threadgill DW et al. (2009). PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibi-tion of cyclin D1. Exp Cell Res 315: 1415-1428.
34. Retelska D, Iseli C, Bucher P, Jongeneel CV, Naef F. (2006). Similarities and differences of polyadenylation signals in human and fly. BMC Genomics 7: 176.
35. Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P et al. (1998). The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 395: 608-612. (Pubitemid 28475715)
36. Stolt CC, Lommes P, Sock E, Chaboissier MC, Schedl A, Wegner M. (2003). The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes Dev 17: 1677-1689. (Pubitemid 36828793)
37. Tago K, Nakamura T, Nishita M, Hyodo J, Nagai S, Murata Y et al. (2000). Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 14: 1741-1749. (Pubitemid 30602993)
38. Topol L, Chen W, Song H, Day TF, Yang Y. (2009). Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. J Biol Chem 284: 3323-3333.
39. Zalzali H, Naudin C, Bastide P, Quittau-Prevostel C, Yaghi C, Poulat F et al. (2008). CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium. Oncogene 27: 7131-7138.
40. Zhang H, Vollmer M, De Geyter M, Litzistorf Y, Ladewig A, Durrenberger M et al. (2000). Characterization of an immortalized human granulosa cell line (COV434). Mol Hum Reprod 6: 146-153. (Pubitemid 30094277)